Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FKC889
- Development stage
- Phase 2
- Lead developer
- Fosun Pharma
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
FKC889 is a CD19-targeted CAR-T cell therapy developed for the treatment of adult patients with relapsed or refractory indolent non-Hodgkin lymphoma, as well as other B-cell malignancies such as mantle cell lymphoma and precursor B-cell acute lymphoblastic leukemia. It is administered intravenously and currently in clinical trials in China[1][2][3]. The mechanism of action involves genetically engineered T cells expressing a chimeric antigen receptor (CAR) that targets CD19 on malignant B cells, leading to their destruction[2].
02
Targets
Beyond the preview
Go deeper on FKC889.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FKC889.